



Applications of Single Cell Sequencing

Trevor Pugh, PhD, FACMG


Canada Research Chair in Translational Genomics
Senior Scientist, Princess Margaret Cancer Centre

Director, Genomics Program, Ontario Institute for Cancer Research

Associate Professor, Dept. of Medical Biophysics, University of Toronto

trevor.pugh@utoronto.ca

We are all made of cells: tissues consist of immune, stromal & many other cell types that interact physically and functionally



Disclosures

Consultant/Honoraria: Merck, AstraZeneca, Illumina, Chrysalis Biomedical Advisors, Canada Pension Plan Investments, PACT Therapeutics

Research funding: Roche/Genentech imCORE

Inventor on patents filed by University Health Network “Hybrid-capture sequencing for determining immune cell clonality”


Director of an academic research core offering single cell profiling (10X Genomics Certified Service Provider, www.pmgenomics.ca)

Learning Objectives


- 1) Understand the conceptual shift in moving from bulk to single cell profiling
- 2) Become acquainted with types, parameters and trade-offs of various single cell technologies
- 3) Using cancer as an example, be exposed to scientific questions and experimental designs utilizing single cell analysis
- 4) Appreciate new scientific and translational opportunities enabled by integrative single cell molecular profiling

Single cell analysis is not new...the revolution is in the scale, completeness, & quantitative nature of genomic technologies


One karyotype in one cell




Quantification of all chromosomes in all cells



In situ hybridization of one transcript




Visualization of 1,000s of genes expressed in all cells





Single-cell analysis reveals heterogeneity in molecular profiles at resolution bulk analysis may not permit

e.g. Six cells with heterogeneous expression of three genes



Bulk analysis detects uniform expression of all three genes




Single-cell analysis directly measures diversity of expression

“A wide variety of single-cell methods have now been developed to measure a broad range of cellular parameters”

Lineage



State

Trajectory




*Considerations and capabilities for
generation of single cell data*

“Exponential scaling of single-cell RNA-seq in the past decade”




Svensson, Vento-Tormo, and Teichmann. Nat Protoc. 2018 Apr;13(4):599-604.

Multiple pathways and technology options to analyze 100s-100,000s of single cells from a variety of sources




Proserpio and Lönnberg. Immunol Cell Biol. 2016 Mar;94(3):225-9.

Multiple pathways and technology options to analyze 100s-100,000s of single cells from a variety of sources




Proserpio and Lönnberg. Immunol Cell Biol. 2016 Mar;94(3):225-9.

Numerous methods to isolate single cells, some more scalable than others



Wang and Song. *Clin Transl Med.* 2017; 6: 10.


Nuclei RNA sequencing now routine: use frozen tissues but drawbacks of no cytoplasm, fewer transcripts, more introns, no cell type enrichment



Slyper et al. *Nat Med* 26, 792–802 (2020). A single-cell and single-nucleus RNA-Seq toolbox for fresh and frozen human tumors.

Two commonly-employed RNA-seq strategies: 10X Genomics End-reads versus Smart-Seq2 Full-length transcripts

10x Genomics Chromium
 \$2-4/cell including sequencing
 100–100,000 cells
 3'-tag method in droplets
 Tagmentation, 3' enrichment,
 Illumina sequencing



SmartSeq2
 \$28-69/cell including sequencing
 96–384 cells
 Full length capture in plates
 Tagmentation, Illumina sequencing





Figure modified from:
*Ziegenhain et al. Mol Cell. 2017
 Feb 16;65(4):631-643.e4.*



*Baran-Gale, Chandra, and
 Kirschner K. Brief Funct
 Genomics. 2017 Nov 8.*

Experimental design balancing transcript coverage, number of genes detected, and library complexity




Baran-Gale, Chandra, and Kirschner K. Brief Funct Genomics. 2017 Nov 8.

Long-read sequencing technologies are applicable to DNA and RNA libraries barcoded at the single cell level



Long-read sequencing technologies can enable complete reconstruction of transcript isoforms at the single cell level






Chen and He. *Medical Review*. <https://doi.org/10.1515/mr-2021-0013>

<https://www.ddw-online.com/full-length-isoform-sequencing-iso-seq-yields-a-more-comprehensive-view-of-gene-activity-1586-201608/>

New spatial technologies enable additional cellular metadata describing physical distances between cell types and cell states



10X Genomics
Xenium



Canonical single-gene markers not always highly expressed in all cells
→ move towards gene sets & multi-modal integration


CD138
also
known as
SDC1

CD139
also
known as
SLAMF7



Numerous bioinformatic tools for quality control, normalization, clustering, ordering single cells, and more


Name	For bulk cell populations or single cells?	Function
Fastqc	Bulk population	Mapping quality control
Kraken	Bulk population	Mapping quality control
GSNAP	Bulk population	Alignment
TopHat	Bulk population	Alignment
HTSeq	Bulk population	Obtaining expression counts
Single-cell normalization	Single cells	Normalization
Monocle	Single cells	Mapping transcripts on differentiation cascade
DESeq	Bulk population	Testing for differential expression
scLVM	Single cells	Accounting for confounding variation in scRNA-seq
Single-cell differential expression	Single cells	Testing for differential expression
Kinetics of transcription	Single cells	Identifying kinetic parameters
Cell Ranger	Single Cells	Analysis suite
Seurat	Single Cells	Analysis suite




Stegle, Teichmann, and Marioni. Nat Rev Genet. 2015 Mar;16(3):133-45.

Cancer as an example

Tumours are dynamic populations of cancer, immune, and other cells that change in frequency and function over the course of treatment



scRNA-seq in practice: How do cancer and immune systems change over time? Is there clinical relevance?



Watching immune systems evolve at the single cell level as cancer develops


Croucher et al. *bioRxiv*. 2021 Jan. 10.22.464971

Single-cell transcriptional analysis of the immune tumour microenvironment during myeloma disease evolution.


Croucher et al. *Nature Communications*. 2021 Nov; 12(6322).

Longitudinal single-cell analysis of a myeloma mouse model identifies subclonal molecular programs associated with progression.

Myeloma begins as a benign condition that progresses to incurable malignancy that tides during treatment and can be tolerated as MRD





V κ *MYC mouse model enables serial dissection of bone marrow microenvironments during transition from MGUS to MM





Collaboration with Michael Sebag (McGill) and Leif Bergsagel (Mayo)
Mouse model published by Chesi et al. Cancer Cell. 2008 Feb; 13(2): 167–180.


Integrated data from >90k cells from 12 mice during disease evolution





T-cells display increased exhaustion signatures as myeloma develops



**Validation
by flow cytometry
in transplantable
mouse model
(Vk12598)**




Combinatorial treatment with anti-LAG3 + anti-PD-1 antibodies delays myeloma progression in transplantable mouse model




Cancer stem cells & subclones inform tumour development & treatment outcome

Richards, Whitley et al. *Nature Cancer*. 2021 Feb.
Gradient of developmental and injury-response transcriptional states defines functional vulnerabilities underpinning glioblastoma heterogeneity


Glioblastomas contain self-renewing cancer stem cells that contribute to tumour initiation and therapeutic resistance



Brain tumour stem cell cultures derived from primary GBMs




Are Brain Tumour Stem Cells comprised of genetic and transcriptional subpopulations?





Single cell RNA-sequencing of 29 patient-derived glioblastoma stem cell cultures

Within each stem cell culture, we find a range of distinct subpopulations



Genome-wide analysis using normal oligodendrocytes as controls uncovers CNVs that *partially* distinguish clusters



Rows are individual cells coloured by transcriptional cluster


Subpopulations with loss of chr10

Patients' GSCs are all different...do they share any common biology?


Developmental Programs





Injury-response Programs




Developmental program (PC1-low)




Injury Response program (PC1-high)




Subpopulations within brain tumour stem cells maintain relative position within the initial developmental/injury-response gradient





Profiling GSCs from many samples is necessary to characterize the full spectrum of possible transcriptional states giving rise to bulk GBM.




GSC gradient between Developmental and Injury Response is recapitulated in cells or nuclei from primary tumors, but bulk tumour cells can obscure



Bulk tumour cells “flow” from their progenitor GSCs’ position on the Developmental/Injury Response Gradient




Functional dependencies identified by genome-wide CRISPR screens reflect Developmental–Injury Response gradient position



TKOv3 library: 70,948 guides targeting 18,053 protein-coding genes in 11 GSCs

Gradients and clusters may be biologically interesting, but is there application for patients?



Single cell RNA-sequencing of 25 patient-derived
BTSC cultures

PharmacODB aggregates gene expression, copy number, and pharmacogenomic profiles of cell lines from multiple high-throughput drug screening studies

PHARMACODB

ABOUT DOCUMENTATION CITE US! GITHUB DOWNLOAD NEWS

PHARMACODB

MINE MULTIPLE CANCER PHARMACOGENOMIC DATASETS

Dataset (eg. 'ccle')

7 DATASETS 41 TISSUES 1,691 CELL LINES 19,933 GENES 759 COMPOUNDS 650,894 EXPERIMENTS


www.pharmacodb.ca

Smirnov, Petr, et al. "PharmacODB: an integrative database for mining in vitro anticancer drug screening studies." *Nucleic Acids Research* (2017).




Smirnov, Petr, et al. "PharmacGx: an R package for analysis of large pharmacogenomic datasets." *Bioinformatics* 32.8 (2015): 1244-1246.

Laboratory of Benjamin Haibe-Kains




Predict drug efficacy score for each cluster, calculate variation of score across each cell, establish dose/response, synergy assay



Predict drug efficacy score for each cluster, calculate variation of score across each cell, establish dose/response, synergy assay




Predict drug efficacy score for each cluster, calculate variation of score across each cell, establish dose/response, synergy assay




Bliss Synergy Value

uM	0.3	0.1	0.03	0.01	0.003	0.001
3	-2.65	-2.12	12.23	0.79	6.78	12.73
1	0.93	1.32	15.96	14.38	20.21	12.75
0.3	0.96	0.6	5.8	-12.31	4.08	5.48
0.1	0.1	-0.16	7.96	-1.19	0.13	-15.21
0.03	0.19	0.082	15.8	-9.59	7.63	-10.63
0.01	0.078	0.38	12.48	4.89	15.42	5.87



Gradients galore: RNA, metabolic, & proteomic profiling all identified continuous biological gradients in glioblastoma




Hubert and Lathia. Nature Cancer 2021.


Multiple, single cell approaches can converge and cross-validate biological signals

Single cell technologies can reveal biology not apparent from bulk approaches





Putting it into practice: Can we prevent early cancer or observe subclonal drug responses in patients?



Computational dissection of cells from a patient with multiple myeloma: direct analysis of cell type, cell state, TCR/BCR, & subclonal copy number



Somatic mutations in scRNA-seq data explain clonal responses



Revisiting the Learning Objectives

- 1) A plethora of single cell technologies have opened windows into cell biology that were closed using bulk approaches that “average out” signal
- 2) The same biology may be measurable using multiple methods
→ tailor experimental approaches to specific scientific questions answerable by available samples & technologies
- 3) Multiple cellular components can be queried from one single cell experiment, e.g. immune & cancer cells inhabiting tumours
- 4) “Fact-check” data quality, integrations, & conclusions using orthogonal experiments, external data sets, & clinical outcomes

Citations - Single Cell RNA-seq (trevor.pugh@utoronto.ca)

Tumour microenvironment

Immune inference

Experimental design

Cell isolation

Technology scaling

10X vs SMART-SEQ2

scRNA-seq technologies

Bioinformatics

Myeloma mouse immune

Myeloma mouse cancer

Glioblastoma stem scRNA-seq

Broad Single Cell Portal

10X Genomics TCR/Ig poster

Human Cell Atlas

Chan-Zuckerberg Initiative

Princess Margaret Genomics

Junttila & de Sauvage. *Nature*. 2013 Sep 19;501(7467):346-54.

Yoshihara et al. *Nat Commun*. 2013;4:2612.

Proserpio and Lönnberg. *Immunol Cell Biol*. 2016 Mar;94(3):225-9.

Wang and Song. *Clin Transl Med*. 2017; 6: 10.

Svensson, Vento-Tormo, and Teichmann. *Nat Protoc*. 2018 Apr;13(4):599-604.

Baran-Gale, Chandra, and Kirschner K. *Brief Funct Genomics*. 2017 Nov 8.

Ziegenhain et al. *Mol Cell*. 2017 Feb 16;65(4):631-643.e4.

Stegle, Teichmann, and Marioni. *Nat Rev Genet*. 2015 Mar;16(3):133-45.

Croucher et al. *bioRxiv*. 2021 Jan. 10.22.464971

Croucher et al. *Nat Comm*. *Nat Comm*. 2021 Nov; 12(6322).

Richards, Whitley, et al. *Nat Cancer*. 2021 Feb.

portals.broadinstitute.org/single_cell/

www.10xgenomics.com/resources/posters

www.humancellatlas.org

www.chanzuckerberg.com/human-cell-atlas

www.pmggenomics.ca

**“Toronto” Single Cell
Analysis Working Group**
sctoronto.slack.com